Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
Medtronic
Boehringer Ingelheim
Colorcon
Harvard Business School

Last Updated: December 7, 2022

CLINICAL TRIALS PROFILE FOR LYSTEDA


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Lysteda

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00113568 ↗ Safety Study of XP12B in Women With Menorrhagia Completed Ferring Pharmaceuticals Phase 3 2005-06-01 The purpose of this study is to evaluate the safety of XP12B in women with heavy menstrual bleeding associated with menorrhagia.
NCT00386308 ↗ Efficacy and Safety Study of XP12B in Women With Menorrhagia Completed Ferring Pharmaceuticals Phase 3 2006-10-01 The purpose of this study is to determine whether XP12B is effective and safe in the treatment of women with heavy menstrual bleeding associated with menorrhagia.
NCT00401193 ↗ Efficacy and Safety of XP12B in Women With Menorrhagia Completed Ferring Pharmaceuticals Phase 3 2006-11-01 The purpose of this study is to determine whether XP12B is effective and safe in the treatment of women with heavy menstrual bleeding associated with menorrhagia.
NCT01190150 ↗ Lysteda Pediatric Research Equity Act (PREA) Pharmacokinetic Study in Adolescent Females With Heavy Menstrual Bleeding Completed Ferring Pharmaceuticals Phase 4 2010-08-01 This is a Phase 4, randomized, 2-way crossover, pharmacokinetic study of Lysteda (tranexamic acid) tablets administered as single doses of 0.65 g and 1.3 g in fasting adolescent female subjects ages 12-16 years with heavy menstrual bleeding.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Lysteda

Condition Name

Condition Name for Lysteda
Intervention Trials
Menorrhagia 6
Heavy Menstrual Bleeding 5
Blood Loss, Surgical 3
Hemorrhage 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Lysteda
Intervention Trials
Hemorrhage 14
Menorrhagia 9
Blood Loss, Surgical 3
Thrombosis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Lysteda

Trials by Country

Trials by Country for Lysteda
Location Trials
United States 159
Turkey 1
United Kingdom 1
Australia 1
Brazil 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Lysteda
Location Trials
California 7
Missouri 7
Georgia 6
Arizona 6
Ohio 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Lysteda

Clinical Trial Phase

Clinical Trial Phase for Lysteda
Clinical Trial Phase Trials
Phase 4 9
Phase 3 7
Phase 2/Phase 3 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Lysteda
Clinical Trial Phase Trials
Completed 14
Recruiting 6
Unknown status 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Lysteda

Sponsor Name

Sponsor Name for Lysteda
Sponsor Trials
Ferring Pharmaceuticals 5
Northwestern University 1
St. Joseph's Hospital and Medical Center, Phoenix 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Lysteda
Sponsor Trials
Other 28
Industry 7
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
Colorcon
McKinsey
Moodys
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.